28,180 Alzheimer's and dementia studies in plain English, each scored out of 100.
Our case suggests that ischemic strokes may be a feature of ARIA and highlights the importance of having a high clinical suspicion for seizures in ARIA. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Recent Phase 3 clinical trials have demonstrated its ability to reduce brain amyloid-β (Aβ) load and slow cognitive decline in patients with early Alzheimer's disease (AD). 4 key findings →
Design: clinical trial Participants: 811 Evidence: low
Full summary, score breakdown and related studies → Original source
Our study suggests that SSAE-3 and SSAE-5 are valid ARIA-E rating scales for use in routine clinical practice by experienced radiologists in specialized settings. 4 key findings →
Participants: 75 Evidence: low
Full summary, score breakdown and related studies → Original source
Alzheimer disease (AD) may develop after the onset of type 2 diabetes mellitus (T2DM), and the risk of AD may depend on the antidiabetic drug administered. 2 key findings →
Participants: 85 Evidence: low
Full summary, score breakdown and related studies → Original source
The results of the cost-effectiveness model presented here suggest that donepezil may be cost-effective but additional controlled data on long-term drug efficacy are needed. 5 key findings →
Design: cross-sectional Evidence: high
Full summary, score breakdown and related studies → Original source
Current long-term use of calcium channel blockers was associated with a significantly reduced risk of a Parkinson disease diagnosis, while the risk was not materially altered for users of angiotensin converting enzyme inhibitors or beta-blockers and, with less statistical precision, for users of angiotensin II antagonists. 3 key findings →
Design: case-control study Evidence: moderate
Full summary, score breakdown and related studies → Original source
These findings demonstrate an association between antecedent statin use and neurofibrillary tangle burden at autopsy. 4 key findings →
Participants: 110 Evidence: low
Full summary, score breakdown and related studies → Original source
Our study is a unique resource of neuroimaging and cognitive measures relevant to change across the adult lifespan. 3 key findings →
Participants: 3,000 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Frequency of participation in cognitively stimulating activities appears to be associated with risk of AD and may partially explain the association of educational and occupational attainment with disease risk. 5 key findings →
Participants: 139 Evidence: low
Full summary, score breakdown and related studies → Original source
Comorbid frontotemporal dementia is a negative prognostic indicator. 5 key findings →
Participants: 139 Evidence: low
Full summary, score breakdown and related studies → Original source
Chronic, low-grade inflammation, or inflammaging, is a crucial contributor to various age-related pathologies and natural processes in aging tissue, including the nervous system. 1 key finding →
Design: cohort study Evidence: moderate
Full summary, score breakdown and related studies → Original source
Our study confirms and extends findings from other countries, demonstrating cross-sectional associations between moderate and poor self-rated vision and dementia in England in all participants aged 50 and older and longitudinally over an 11-year period in those aged 50 to 69. 3 key findings →
Design: cohort study Evidence: moderate
Full summary, score breakdown and related studies → Original source
Alzheimer's disease and related dementias lack effective treatment or cures and are major public health challenges. 2 key findings →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source
During the study period, there were 1175 DDE hospital admissions. 1 key finding →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source
The associations of particulate matter (PM) pollution with the morbidity of overall and subtypes of mental disorders (MDs), as well as the corresponding morbidity burden, remain understudied, especially in developing countries. 5 key findings →
Participants: 10,947 Evidence: low
Full summary, score breakdown and related studies → Original source
A discussion with theoretical and possible future research directions is provided and it is clear that the need is not only of longitudinal population studies and of better knowledge of epigenetics markers but, especially, of environmental policy interventions based on the green economy. 3 key findings →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source
[(18)F]flutemetamol amyloid PET detects primarily advanced stages of Aβ pathology in preclinical and symptomatic AD cases. 1 key finding →
Design: clinical trial Participants: 68 Evidence: moderate
Full summary, score breakdown and related studies → Original source
The purpose of this study was to identify the specific patient comorbidities that are associated with an increased risk of periprosthetic joint infection and of ninety-day postoperative mortality in U.S. Results Comorbid conditions associated with an increased adjusted risk of periprosthetic joint infection (in decreasing order of significance, p < 0.05 for all comparisons) were rheumatologic disease (hazard ratio [HR] = 1.71), obesity (HR = 1.73), coagulopathy (HR = 1.58), and preoperative anemia (HR = 1.36). 4 key findings →
Participants: 40,919 Evidence: low
Full summary, score breakdown and related studies → Original source
In this study, prevalence rates for ADRD mirrored population estimates. 4 key findings →
Participants: 3,934 Evidence: low
Full summary, score breakdown and related studies → Original source
When validated with subjects diagnosed using an official test, the model achieves COVID-19 sensitivity of 98.5% with a specificity of 94.2% (AUC: 0.97). 5 key findings →
Participants: 19 Evidence: low
Full summary, score breakdown and related studies → Original source
Alzheimer's disease (AD) is one of the most common neurodegenerative diseases. 1 key finding →
Participants: 647 Evidence: low
Full summary, score breakdown and related studies → Original source
Alzheimer's disease (AD) is an irreversible brain degenerative disorder affecting people aged older than 65 years. 1 key finding →
Participants: 339 Evidence: low
Full summary, score breakdown and related studies → Original source
Inappropriate drug use was common in our study cohort. 4 key findings →
Participants: 519 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Home-time, which can be readily calculated from administrative claims data, is substantially reduced for many patients following hospitalization for HF and is highly correlated with traditional time-to-event mortality and hospitalization outcomes. 3 key findings →
Participants: 59,736 Evidence: low
Full summary, score breakdown and related studies → Original source
IBS is associated with an increased risk of dementia, and this effect is obvious only in patients who are ≥50 years old. 4 key findings →
Participants: 192 Evidence: low
Full summary, score breakdown and related studies → Original source
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 28,180 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 28,180 records, built mostly from automated pulls of Europe PMC (61.7% of the library) and OpenAlex (18.1%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →